SCHEMBL25602402

SCHEMBL25602402

O=C(Nc1ccc2c(c1)C1C=CCC1C(c1ccc([N+](=O)[O-])cc1)N2)c1ccc(Cl)cc1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ USP7 Q93009 2/20 0.58
▸ HPN P05981 2/20 0.58
▸ CYBB P04839 1/20 0.52
▸ NR4A1 P22736 2/20 0.49
▸ PTPN7 P35236 3/20 0.47
▸ GAPDH P04406 1/20 0.47
▸ HSPA1A P0DMV8 1/20 0.47
▸ HSPA8 P11142 1/20 0.47
▸ CD44 P16070 1/20 0.47
▸ MSN P26038 1/20 0.47
▸ EZH2 Q15910 1/20 0.47
▸ FPR1 P21462 1/20 0.46
▸ CDK2 P24941 1/20 0.46
▸ AR P10275 1/20 0.46
▸ POLB P06746 4/20 0.46
▸ MAPT P10636 4/20 0.46
▸ GRK6 P43250 1/20 0.44
▸ CDC25B P30305 1/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25602290 0.92 USP7 (0.56) USP7HPNCYBBNR4A1PTPN7
SCHEMBL25602292 0.86 USP7 (0.61) USP7HPNCYBBNR4A1PTPN7
SCHEMBL25602294 0.83 USP7 (0.67) USP7HPNCYBBNR4A1PTPN7
SCHEMBL25602301 0.80 USP7 (0.80) USP7HPNCYBBNR4A1PTPN7
SCHEMBL25602307 0.78 USP7 (0.87) USP7HPNCYBBNR4A1PTPN7
SCHEMBL14542508 0.76 NR4A1 (0.80) USP7HPNCYBBNR4A1PTPN7
SCHEMBL17704810 0.74 USP7 (0.73) USP7HPNCYBBNR4A1PTPN7
SCHEMBL25602310 0.74 CYBB (0.74) USP7HPNCYBBNR4A1PTPN7
SCHEMBL2031914 0.74 HPN (1.00) USP7HPNCYBBNR4A1PTPN7
SCHEMBL25602302 0.74 USP7 (0.57) USP7HPNCYBBNR4A1PTPN7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11672794-B2 Therapeutic targeting of the BAP1 complex in cancer NORTHWESTERN UNIVERSITY (US) 2023-06-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11672794-B2 Therapeutic targeting of the BAP1 complex in cancer BAP1, MCL1, STUB1 USP7 113/4885HPN 1581/4885CYBB 1940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback